TW200505414A - Anti-tumor agent and process for producing the same - Google Patents
Anti-tumor agent and process for producing the sameInfo
- Publication number
- TW200505414A TW200505414A TW093106868A TW93106868A TW200505414A TW 200505414 A TW200505414 A TW 200505414A TW 093106868 A TW093106868 A TW 093106868A TW 93106868 A TW93106868 A TW 93106868A TW 200505414 A TW200505414 A TW 200505414A
- Authority
- TW
- Taiwan
- Prior art keywords
- tumor
- tumor agent
- polymeric
- sma
- low molecule
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001718 carbodiimides Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229960001221 pirarubicin Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003147852 | 2003-05-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200505414A true TW200505414A (en) | 2005-02-16 |
| TWI332834B TWI332834B (enExample) | 2010-11-11 |
Family
ID=33475378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093106868A TW200505414A (en) | 2003-05-26 | 2004-03-15 | Anti-tumor agent and process for producing the same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7682630B2 (enExample) |
| EP (1) | EP1627645B1 (enExample) |
| JP (1) | JP4669393B2 (enExample) |
| CN (1) | CN1697663A (enExample) |
| AU (1) | AU2004241830B9 (enExample) |
| CA (1) | CA2489259C (enExample) |
| ES (1) | ES2642179T3 (enExample) |
| HU (1) | HUE035003T2 (enExample) |
| PT (1) | PT1627645T (enExample) |
| TW (1) | TW200505414A (enExample) |
| WO (1) | WO2004103409A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128959B2 (en) | 2005-04-18 | 2012-03-06 | Hiroshi Maeda | Polymeric pharmaceutical agent for treatment of cancer and method for production of the same |
| ES2357325T3 (es) * | 2005-09-12 | 2011-04-25 | Yogesh Bendale. N | Platino biológico novedoso, procedimiento de preparación, procedimiento de administración para tratamiento antitumoral. |
| FR2922452B1 (fr) * | 2007-10-19 | 2010-01-22 | Coatex Sas | Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations |
| JP2010013411A (ja) * | 2008-07-05 | 2010-01-21 | Hiroshi Maeda | 抗炎症剤 |
| DK2774625T3 (en) | 2011-09-05 | 2017-06-12 | Hiroshi Maeda | POLYMER TYPE FLUORESCING MOLECULE PROBE |
| JP6083738B2 (ja) * | 2013-03-06 | 2017-02-22 | 公立大学法人大阪市立大学 | ホウ素中性子捕捉療法用組成物およびその製造方法 |
| CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58149903A (ja) | 1982-02-27 | 1983-09-06 | Kuraray Co Ltd | ネオカルチノスタチン複合体の製造法 |
| DE3367921D1 (en) | 1982-02-27 | 1987-01-15 | Kuraray Co | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
| JPS6075499A (ja) | 1983-08-08 | 1985-04-27 | Kuraray Co Ltd | ネオカルチノスタチン誘導体及びその製造法 |
| JP2556865B2 (ja) * | 1986-09-19 | 1996-11-27 | 山之内製薬株式会社 | ネオカルチノスタチン誘導体の非注射投与用組成物 |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| CA2255615C (en) * | 1996-05-22 | 2006-08-29 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel |
| GB0001481D0 (en) | 2000-01-21 | 2000-03-15 | Theryte Ltd | System for delivering a medicament |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
-
2004
- 2004-02-02 WO PCT/JP2004/000993 patent/WO2004103409A1/ja not_active Ceased
- 2004-02-02 CA CA2489259A patent/CA2489259C/en not_active Expired - Fee Related
- 2004-02-02 EP EP04707295.4A patent/EP1627645B1/en not_active Expired - Lifetime
- 2004-02-02 PT PT47072954T patent/PT1627645T/pt unknown
- 2004-02-02 JP JP2005506303A patent/JP4669393B2/ja not_active Expired - Fee Related
- 2004-02-02 CN CNA2004800006708A patent/CN1697663A/zh active Pending
- 2004-02-02 HU HUE04707295A patent/HUE035003T2/en unknown
- 2004-02-02 AU AU2004241830A patent/AU2004241830B9/en not_active Expired
- 2004-02-02 US US10/514,892 patent/US7682630B2/en not_active Expired - Fee Related
- 2004-02-02 ES ES04707295.4T patent/ES2642179T3/es not_active Expired - Lifetime
- 2004-03-15 TW TW093106868A patent/TW200505414A/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1627645A1 (en) | 2006-02-22 |
| TWI332834B (enExample) | 2010-11-11 |
| PT1627645T (pt) | 2017-11-23 |
| AU2004241830B9 (en) | 2010-04-22 |
| WO2004103409A1 (ja) | 2004-12-02 |
| CA2489259A1 (en) | 2004-12-02 |
| AU2004241830B2 (en) | 2010-02-25 |
| CN1697663A (zh) | 2005-11-16 |
| US7682630B2 (en) | 2010-03-23 |
| ES2642179T3 (es) | 2017-11-15 |
| EP1627645A4 (en) | 2008-12-24 |
| CA2489259C (en) | 2011-08-30 |
| US20050208136A1 (en) | 2005-09-22 |
| HUE035003T2 (en) | 2018-05-02 |
| EP1627645B1 (en) | 2017-08-23 |
| AU2004241830A1 (en) | 2004-12-02 |
| JPWO2004103409A1 (ja) | 2006-07-20 |
| JP4669393B2 (ja) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025066807A (ja) | 生体直交型組成物 | |
| US20170368194A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
| Ha et al. | Prodrugs forming multifunctional supramolecular hydrogels for dual cancer drug delivery | |
| AU2014273983A1 (en) | Cyclodextrin-based polymers for the therapeutic delivery | |
| CN102266288A (zh) | 一种基于胆固醇修饰的还原敏感性肿瘤靶向脂质体 | |
| JPWO1999061061A1 (ja) | 薬物複合体 | |
| WO2003022210A3 (en) | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | |
| JP2009521515A (ja) | 腫瘍細胞における耐性を克服するためのタンパク質ベースの担体システム | |
| JP2017505800A5 (enExample) | ||
| TW200505414A (en) | Anti-tumor agent and process for producing the same | |
| Pradhan et al. | Dendrimer grafted albumin nanoparticles for the treatment of post cerebral stroke damages: a proof of concept study | |
| CN104367556B (zh) | 一种能提供一氧化氮的透明质酸硝酸酯去氧胆酸聚合物胶束的制备方法及其应用 | |
| TWI404527B (zh) | 治療癌症之金屬-多醣體共軛物之組成與其合成方法 | |
| JP2015505557A (ja) | 治療的送達のためのシクロデキストリンに基づく重合体 | |
| CN103768081B (zh) | 一种羟乙基淀粉-阿霉素键合药的制备方法 | |
| CN101160354B (zh) | 高分子型癌症治疗用药及其制造方法 | |
| Ku et al. | pH-Responsive globular poly (ethylene glycol) for photodynamic tumor therapy | |
| CN106214639B (zh) | 一种壳聚糖枝接西替利嗪纳米胶束的制备方法 | |
| CN102935237A (zh) | 阿霉素键合药及其制备方法 | |
| CN1973902A (zh) | 以人参多糖为载体的的抗肿瘤药物阿霉素复合物及制备方法 | |
| CN108635589A (zh) | 一种葛根素透明质酸纳米胶束的制备方法 | |
| 최종선 et al. | Upconversion Nanoparticles for Deep Tissue Cancer Therapy and Imaging | |
| 김다은 et al. | S-Nitrosoglutathione-Conjugated Hyaluronic Acid Nanoparticles as a Stable Intracellular Carrier of Nitric Oxide | |
| 김민희 et al. | Fabrication of Fast Degradable Silk Fibroin-Hydroxyapatite Composite Scaffolds by Irradiation | |
| 김유경 et al. | Synthesis and characterization of a bioreducible cationic AB₂ miktoarm polymer for efficient gene delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |